Newswire (Published: Monday, December 11, 2017, Received: Thursday, December 7, 2017, 12:43:39 PM CST)

Word Count: 454

New Findings on Prostate Cancer from University Hospital Summarized (Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting out of Braunschweig, Germany, by NewsRx editors, research stated, "We investigated the health-related quality of life (HRQoL) of long-term prostate cancer patients who received leuprorelin acetate in microcapsules (LAM) for androgen-deprivation therapy (ADT). The observational study was carried out by 30 office-based German urologists in 536 prostate cancer (PCa) patients treated for greater than or equal to5 years with LAM and in 116 patients of an age-matched control group (CG)."

Our news journalists obtained a quote from the research from University Hospital, "Data on HRQoL and health status was collected prospectively using validated questionnaires QLQ-C30, QLQ-PR25 and Karnofsky Index. Data on effectiveness (clinical response, prostate specific antigen [PSA], testosterone) and safety was collected retrospectively from patients' health records. We used descriptive statistics to analyze the data. The mean treatment duration was 8.6 years (range 4.5-19.8 years). General health status (QLQ-C30) was comparable for both groups. Differences were observed regarding physical -and role functioning. ADT patients rated single items slightly worse than CG. Karnofsky-Index showed comparable high values (median of 90%). QLQ-PR25 revealed more PCa-related symptoms for ADT patients. Within 6 months, median PSA level declined >90% and median testosterone levels declined below castration level from 4.0 to 0.2 ng/mL. Clinical response (European Organisation for Research and Treatment of Cancer criteria) was observed in at least 90% of ADT patients."

According to the news editors, the research concluded: "Long-term ADT with LAM is a well-accepted, tolerated, effective, and low-burden treatment option for patients with advanced, hormone-sensitive PCa."

For more information on this research see: Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis. Urologia Internationalis, 2017;():. (Karger - www.karger.com/; Urologia Internationalis - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=224282)

Our news journalists report that additional information may be obtained by contacting P.G. Hammerer, Dept. of Urology, Academic Hospital, Braunschweig, Germany (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1159/000479434. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Europe, Germany, Oncology, Braunschweig, Prostate Cancer, Quality of Life, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Western Europe
Germany
Europe

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process